The study will be led by principal investigator professor Noemi Lois, MD, PhD, FRCS (Ed), FRCOphth, at Queen’s University Belfast, in over 20 clinical sites, and plans to enroll 264 patients across ...

Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics). Ahead of the Clinical Trials at the Summit (CTS) meeting in Las ...

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation. Today Nanoscope Therapeutics announced its ...

Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement. In a ...

The use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability. The ...

In her keynote address, Prof Schmidt-Erfurth focused on new artificial intelligence tools and their usage in addressing age-related macular degeneration. At this year's meeting of the European Society ...

Recapping a recent conversation led by Dilsher S. Dhoot, MD. In May 2025, Dilsher S. Dhoot, MD, moderated a Case-Based Roundtable® that brought together practicing retina specialists and residents ...

Tenpoint Therapeutics’ YUVEZZI, projected to launch in the US in Q2 2026, represents the first fixed-dose combination eye drop developed to enhance near vision through pupil modulation with once-daily ...

Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao highlight gene therapy as a future treatment of neovascular AMD and DME and how it will significantly reduce the burden on patients.

The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release. Astellas Pharma Inc. announced the United States Food and Drug Administration (FDA) has ...

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...

The ReNEW study for dry AMD is evaluating the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of elamipretide, wa first-in-class mitochondria-targeted investigational ...